The Ebola epidemic in West Africa could infect 20,000 people, warning that an international effort costing almost half a billion dollars is needed.» Read More
LONDON, Aug 10- A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists.
All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.
NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.
An investigator linked to the U.K. drug giant GSK was convicted in a case that many say highlights the risks of conducting due diligence in China.
NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..
Some of Monday's midday movers:
*Advair restored to Express Scripts 2015 formulary list. LONDON, Aug 4- GlaxoSmithKline received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015..
*Investors focused on possible Pfizer return. LONDON, July 31- AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.
LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.
*FDA lists 10 violations at Taiwan plant. July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.
GSK's chief executive has opened the possibility of the group being broken up as he pushes through a sweeping overhaul of Britain's biggest drugmaker.
LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.
GlaxoSmithKline faces new corruption allegations in Syria, where it has been accused of paying bribes to secure business.
LONDON, July 24- GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by Reuters.
LONDON, July 24- GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.
LONDON, July 24- GlaxoSmithKline is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.
Some of Wednesday's midday movers:
LONDON, July 23- Britain's fraud office is working with authorities in China in a first for such Anglo-Chinese cooperation as it carries out its own investigation into alleged corruption at drugmaker GlaxoSmithKline.
European shares closed higher on Wednesday amid corporate earnings news and ongoing turmoil in Gaza and Ukraine.